Paragraf, the only company in the world to mass produce graphene electronics, completed the acquisition of Cardea Bio, a producer of graphene-based biocompatible chips. Financial terms were not disclosed. “The world-leading IP and expertise in graphene-electronic-based molecular detection using CRISPR and other bioassay methods from Cardea Bio, combined with Paragraf’s ground-breaking developments in scalable graphene production processes will deliver a strong pipeline of biosensing products aimed at solving major global challenges,” Simon Thomas, Paragraf CEO and Co-founder.